Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NVCR

NovoCure Ltd

Dec 24 • 04:00PM ET

30.97

Dollar change +0.48
Percentage change 1.57	%

Healthcare • Medical Devices • United Kingdom • NASD

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: IWM VTI VB VBK IWO VXF IBB IHI SCHA CGGR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.39	Insider Own	10.03%	Shs Outstand	108.10M	Perf Week	-3.51%
Market Cap	3.35B	Forward P/E	-	EPS next Y	-1.63	Insider Trans	-0.02%	Shs Float	97.35M	Perf Month	74.68%
Income	-149.78M	PEG	-	EPS next Q	-0.36	Inst Own	85.90%	Short Float	5.33%	Perf Quarter	94.17%
Sales	577.74M	P/S	5.80	EPS this Y	32.60%	Inst Trans	-0.03%	Short Ratio	3.93	Perf Half Y	70.54%
Book/sh	3.34	P/B	9.28	EPS next Y	-23.80%	ROA	-12.65%	Short Interest	5.19M	Perf Year	132.86%
Cash/sh	8.91	P/C	3.48	EPS next 5Y	-	ROE	-39.70%	52W Range	11.70 - 34.13	Perf YTD	107.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.97%	ROI	-31.27%	52W High	-9.26%	Beta	0.72
Dividend TTM	-	Quick Ratio	1.44	Sales past 5Y	17.16%	Gross Margin	76.55%	52W Low	164.70%	ATR (14)	2.02
Dividend Ex-Date	-	Current Ratio	1.49	EPS Y/Y TTM	25.11%	Oper. Margin	-26.00%	RSI (14)	64.15	Volatility	6.13% 8.27%
Employees	1453	Debt/Eq	1.87	Sales Y/Y TTM	14.63%	Profit Margin	-25.93%	Recom	1.57	Target Price	35.00
Option/Short	Yes / Yes	LT Debt/Eq	0.33	EPS Q/Q	39.07%	Payout	-	Rel Volume	0.24	Prev Close	30.49
Sales Surprise	7.74%	EPS Surprise	16.12%	Sales Q/Q	21.81%	Earnings	Oct 30 BMO	Avg Volume	1.32M	Price	30.97
SMA20	8.12%	SMA50	43.13%	SMA200	68.14%	Trades		Volume	312,354	Change	1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98
Jan-20-22	Upgrade	Truist	Hold → Buy	$125
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line	$82

Show Previous Ratings

Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
04:23PM	Loading…
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Medical Device Network)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)
07:00AM	Loading…
07:00AM	FDA Approves Novocures Innovative HFE Transducer Arrays for Use With Optune Gio for Glioblastoma (Business Wire)
Oct-31-24 07:30AM	NovoCures Strong Q3 and Leadership Changes in 2024 (TipRanks) -10.65%
03:04AM	NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... (GuruFocus.com)
Oct-30-24 11:00PM	NovoCure (NVCR) Q3 2024 Earnings Call Transcript (Motley Fool)
08:15AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:02AM	Novocure Appoints Christoph Brackmann as Chief Financial Officer (Business Wire)
07:00AM	Novocure Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-17-24 10:52AM	Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment (GuruFocus.com) -5.43%
08:00AM	NovoCure scoops FDA approval on wearable for metastatic cancer treatment (Clinical Trials Arena)
Oct-16-24 04:21PM	Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. (Investor's Business Daily)
08:16AM	Novocure wins FDA approval for electric field device in lung cancer (BioPharma Dive)
07:28AM	FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients (Benzinga)
06:26AM	Novocure shares soar 33% as FDA approves lung cancer treatment (Investing.com)
03:45AM	NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks)
06:09PM	Loading…
Oct-15-24 06:09PM	Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment (Investor's Business Daily) +10.71%
04:43PM	FDA Approves Novocure's Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Oct-01-24 07:00AM	Novocure to Report Third Quarter 2024 Financial Results (Business Wire)
Sep-09-24 07:00AM	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy (Business Wire)
Sep-06-24 05:19PM	Why NovoCure Stock Dived by 13% This Week (Motley Fool) -6.48%
Sep-03-24 07:00AM	Novocure Announces Planned CEO Transition (Business Wire) -13.84%
Aug-28-24 07:00AM	Novocure to Participate in 2024 Wells Fargo Healthcare Conference (Business Wire) +9.61%
Aug-16-24 09:55AM	Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet (Zacks) -5.34%
Aug-14-24 07:00AM	Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer (Business Wire)
Aug-12-24 03:59PM	Biotech stocks: Which drugmakers are worth a buy? (Yahoo Finance Video)
Jul-30-24 09:55AM	Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade (Zacks) +12.24%
Jul-25-24 05:30PM	NovoCure (NVCR) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:11AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-16-24 08:45AM	CereVasc Announces Appointments of New Directors (PR Newswire) +7.17%
Jul-14-24 12:16PM	30 Wealthiest People in Switzerland (Insider Monkey)
Jul-01-24 07:00AM	Novocure to Report Second Quarter 2024 Financial Results (Business Wire)
Jun-14-24 10:44AM	Cramer's Lightning Round: Novocure, PayPal, AeroVironment (CNBC TV)
Jun-03-24 08:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival (Business Wire) +8.54%
May-23-24 05:05PM	TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany (Business Wire) -5.86%
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace) +13.01%
May-10-24 05:14PM	Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.17%
May-03-24 12:08PM	NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:00AM	NovoCure (NVCR) Q1 2024 Earnings Call Transcript (Motley Fool)
May-02-24 01:19PM	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue (MT Newswires) +11.38%
11:56AM	NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:45AM	NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported (GuruFocus.com)
08:25AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:28AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon (Business Wire)
07:00AM	Novocure Reports First Quarter 2024 Financial Results (Business Wire)
Apr-25-24 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-24-24 10:45AM	Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 (Business Wire)
Apr-05-24 07:00AM	Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 (Business Wire)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade (Zacks)
07:00AM	Novocure to Report First Quarter 2024 Financial Results (Business Wire)
Mar-30-24 06:34AM	Why NovoCure Stock Soared 18.3% This Week (Motley Fool)
Mar-28-24 11:50AM	Why Novocure Stock Is Jumping Today (Motley Fool) +6.76%
05:01AM	NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Mar-27-24 04:08PM	Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish (Investor's Business Daily) +12.01%
09:29AM	Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
09:16AM	Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment (Investor's Business Daily)
07:14AM	UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:12AM	Novocure's device shown to slow cancer progression in the brain in trial (Reuters)
07:05AM	Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
Mar-13-24 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO (Business Wire)
Feb-23-24 11:43AM	NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 12:15PM	NovoCure (NVCR) Q4 2023 Earnings Call Transcript (Motley Fool)
08:25AM	NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:36AM	NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:23AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (Business Wire)
Jan-19-24 07:46AM	Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength? (Zacks)
Jan-18-24 02:19PM	Why Is Cancer Focused Novocure Stock Trading Higher Today? (Benzinga) +16.75%
07:00AM	Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer (Business Wire)
Jan-11-24 09:55AM	Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know (Zacks)
Jan-09-24 07:00AM	Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma (Business Wire)
Jan-08-24 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update (Business Wire) +11.61%
Jan-04-24 04:05PM	Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer (Business Wire)
Dec-27-23 07:00AM	Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +12.20%
Dec-08-23 04:09AM	15 Best Falling Stocks To Buy Now (Insider Monkey)
Dec-04-23 04:46PM	The Top and Bottom Stocks of 2023 (Investopedia)
Nov-28-23 10:51AM	Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts (InvestorPlace)
07:30AM	Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability (Business Wire)
Nov-21-23 07:00AM	Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-23 09:09AM	11 Best Undervalued UK Stocks To Buy Now (Insider Monkey) +12.48%

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paravasthu Mukund	Chief Operating Officer	Nov 02 '24	Sale	16.69	44	734	3,459	Nov 06 04:27 PM
Puri Michal Nath	Chief Human Resources Officer	Oct 31 '24	Sale	15.79	810	12,792	110,093	Nov 04 04:34 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Nov 01 '24	Sale	15.94	598	9,531	161,236	Nov 04 04:34 PM
Paravasthu Mukund	Chief Operating Officer	Nov 01 '24	Sale	15.88	160	2,540	3,503	Nov 04 04:32 PM
Cordova Ashley	Chief Financial Officer	Aug 02 '24	Sale	20.14	688	13,857	219,179	Aug 05 04:25 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Jun 05 '24	Option Exercise	22.82	124,373	2,838,192	124,373	Jun 07 04:06 PM
VERNON W ANTHONY	Director	Jun 04 '24	Sale	23.89	964	23,033	164,833	Jun 06 05:43 PM
Scannell Timothy J	Director	Jun 04 '24	Sale	23.89	964	23,027	2,964	Jun 06 05:42 PM
LEUNG GABRIEL	Director	Jun 04 '24	Sale	23.89	964	23,025	78,175	Jun 06 05:42 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 01 '24	Sale	16.03	2,107	33,769	252,452	Mar 05 04:09 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 04 '24	Sale	16.01	1,217	19,484	251,235	Mar 05 04:09 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 01 '24	Sale	16.03	1,679	26,909	160,938	Mar 05 04:08 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 04 '24	Sale	16.01	840	13,448	160,098	Mar 05 04:08 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '24	Sale	16.14	2,078	33,545	162,617	Feb 29 04:38 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Feb 28 '24	Sale	16.14	2,303	37,177	254,559	Feb 29 04:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience